High CTHRC1 expression may be closely associated with angiogenesis and indicates poor prognosis in lung adenocarcinoma patients

被引:16
作者
Chen, Yangshan [1 ]
Sun, Yu [1 ]
Cui, Yongmei [1 ]
Lei, Yiyan [2 ]
Jiang, Neng [1 ]
Jiang, Wenting [1 ]
Wang, Han [1 ]
Chen, Lili [1 ]
Luo, Jiping [1 ]
Chen, Yanyang [1 ]
Tang, Kejing [3 ]
Zhou, Chengzhi [4 ]
Ke, Zunfu [1 ,5 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, 58 Zhongshan Second Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept OfThorac Surg, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Resp Med, Guangzhou 510080, Guangdong, Peoples R China
[4] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou 510080, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung adenocarcinoma (LUAD); Collagen triple helix repeat containing 1 (CTHRC1); Vascular endothelial growth factor (VEGF); Microvessel density (MVD); Tumor angiogenesis; TRIPLE-HELIX REPEAT; COLORECTAL-CANCER; TUMOR ANGIOGENESIS; METASTASIS; CARCINOMA; INVASION; IMPACT; SURVIVAL; PROTEIN; BREAST;
D O I
10.1186/s12935-019-1041-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to investigate the prognostic value of the potential biomarker collagen triple helix repeat containing 1 (CTHRC1) in lung adenocarcinoma (LUAD) patients. Methods A total of 210 LUAD patients diagnosed between 2003 and 2016 in the Department of Pathology of the First Affiliated Hospital of Sun Yat-sen University were included in this study. The expression of CTHRC1 and vascular endothelial growth factor (VEGF), and microvessel density (MVD, determined by CD34 immunostaining) were evaluated by immunohistochemistry in LUAD tissues. The association between the expression of these proteins and clinicopathological features or clinical outcomes was analyzed. Results Here, we confirmed that CTHRC1 expression was associated with prognosis and can serve as a significant predictor for overall survival (OS) and progression-free survival (PFS) in LUAD. Additionally, we observed that CTHRC1 expression was positively associated with tumor angiogenesis markers, such as VEGF expression (P < 0.001) and MVD (P < 0.01). Then, we performed gene set enrichment analysis (GESA) and cell experiments to confirm that enhanced CTHRC1 expression can promote VEGF levels. Based on and cox regression analysis, a predictive model that included CTHRC1, VEGF and MVD was constructed and confirmed as a more accurate independent predictor for OS (P = 0.001) and PFS (P < 0.001) in LUAD than other parameters. Conclusions These results demonstrated that high CTHRC1 expression may be closely related to tumor angiogenesis and poor prognosis in LUAD. The predictive model based on the CTHRC1 level and tumor angiogenesis markers can be used to predict LUAD patient prognosis more accurately.
引用
收藏
页数:14
相关论文
共 51 条
[1]  
Abidin Aidalena Z, 2010, Ther Adv Med Oncol, V2, P25, DOI 10.1177/1758834009356014
[2]   The lung microenvironment: an important regulator of tumour growth and metastasis [J].
Altorki, Nasser K. ;
Markowitz, Geoffrey J. ;
Gao, Dingcheng ;
Port, Jeffrey L. ;
Saxena, Ashish ;
Stiles, Brendon ;
McGraw, Timothy ;
Mittal, Vivek .
NATURE REVIEWS CANCER, 2019, 19 (01) :9-31
[3]   Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses [J].
Bais, Carlos ;
Mueller, Barbara ;
Brady, Mark F. ;
Mannel, Robert S. ;
Burger, Robert A. ;
Wei, Wei ;
Marien, Koen M. ;
Kockx, Mark M. ;
Husain, Amreen ;
Birrer, Michael J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11)
[4]   Overexpression of CTHRC1 in Hepatocellular Carcinoma Promotes Tumor Invasion and Predicts Poor Prognosis [J].
Chen, Yu-Ling ;
Wang, Ting-Huang ;
Hsu, Hey-Chi ;
Yuan, Ray-Hwang ;
Jeng, Yung-Ming .
PLOS ONE, 2013, 8 (07)
[5]   Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer [J].
Choi, Chang-Min ;
Jang, Se-Jin ;
Park, Seong-Yeol ;
Choi, Yong-Bock ;
Jeong, Jae-Heon ;
Kim, Dae-Seok ;
Kim, Hyun-Kyoung ;
Park, Kang-Seo ;
Nam, Byung-Ho ;
Kim, Hyeong-Ryul ;
Kim, Soo-Youl ;
Hong, Kyeong-Man .
MOLECULAR CANCER, 2011, 10
[6]   How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer? [J].
Coate, Linda E. ;
Leighl, Natasha B. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2011, 12 (01) :1-11
[7]   Development and Validation of a Novel Signature to Predict Overall Survival in "Driver Genenegative" Lung Adenocarcinoma (LUAD): Results of a Multicenter Study [J].
Cui, Yongmei ;
Fang, Wenfeng ;
Li, Chaofeng ;
Tang, Kejing ;
Zhang, Jian ;
Lei, Yiyan ;
He, Weiling ;
Peng, Sui ;
Kuang, Ming ;
Zhang, Hui ;
Chen, Lili ;
Xu, Di ;
Tang, Cuilan ;
Zhang, Wenhui ;
Zhu, Yuxin ;
Jiang, Wenting ;
Jiang, Neng ;
Sun, Yu ;
Chen, Yangshan ;
Wang, Han ;
Lai, Yingrong ;
Li, Shuhua ;
He, Qiong ;
Zhou, Jianwen ;
Zhang, Yang ;
Lin, Millicent ;
Chen, Honglei ;
Zhou, Chenzhi ;
Wang, Chunlin ;
Wang, Jianhong ;
Zou, Xuenong ;
Wang, Liantang ;
Ke, Zunfu .
CLINICAL CANCER RESEARCH, 2019, 25 (05) :1546-1556
[8]   Microenvironmental regulation of tumour angiogenesis [J].
de Palma, Michele ;
Biziato, Daniela ;
Petrova, Tatiana V. .
NATURE REVIEWS CANCER, 2017, 17 (08) :457-474
[9]   Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR [J].
Fleige, Simone ;
Walf, Vanessa ;
Huch, Silvia ;
Prgomet, Christian ;
Sehm, Julia ;
Pfaffl, Michael W. .
BIOTECHNOLOGY LETTERS, 2006, 28 (19) :1601-1613
[10]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182